A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines
Withdrawn
- Conditions
- Chronic Migraine, Headache
- Interventions
- Biological: OnabotulinumtoxinA
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Allergan
- Registration Number
- NCT01749423
An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
Completed
- Conditions
- Ocular HypertensionGlaucoma, Open-Angle
- Interventions
- Drug: Prostaglandin Analogue -Containing IOP-Lowering Therapy
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 358
- Registration Number
- NCT01735214
AGN-199201 for the Treatment of Erythema With Rosacea
Phase 2
Completed
- Conditions
- RosaceaErythema
- Interventions
- Drug: AGN-199201 VehicleDrug: AGN-199201 Dose BDrug: AGN-199201 Dose ADrug: AGN-199201 Dose C
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 357
- Registration Number
- NCT01735201
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Phase 4
Completed
- Conditions
- Conjunctivitis, Allergic
- Interventions
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 157
- Registration Number
- NCT01732757
An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: OPTIVE PLUS®
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1209
- Registration Number
- NCT01711424
Bimatoprost in the Treatment of Eyelash Hypotrichosis
Phase 3
Completed
- Conditions
- Idiopathic Eyelash Hypotrichosis
- Interventions
- Drug: bimatoprost formulation A solutionDrug: bimatoprost solution 0.03 %Drug: vehicle of bimatoprost formulation A solutionDrug: vehicle of bimatoprost solution 0.03 %
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 464
- Registration Number
- NCT01698554
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 641
- Registration Number
- NCT01686581
- Locations
- 🇩🇪
Kathrin Krome, Bamberg, Germany
🇩🇪Ulrike Kirchhöfer, Erfurt, Germany
🇩🇪Hans-Dieter Zug, Böblingen, Germany
Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye
Phase 4
Completed
- Conditions
- Dry Eye
- Interventions
- Device: Punctal Plug
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 30
- Registration Number
- NCT01684436
Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds
Not Applicable
Completed
- Conditions
- Moderate to Severe Nasolabial Folds
- Interventions
- Device: Crosslinked hyaluronic acid dermal filler
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 70
- Registration Number
- NCT01680497
A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia
Phase 2
Terminated
- Conditions
- Neuralgia, Postherpetic
- Interventions
- Drug: AGN-214868Drug: AGN-214868 Placebo (Vehicle)
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Allergan
- Target Recruit Count
- 280
- Registration Number
- NCT01678924
- Locations
- 🇵🇱
NZOZ Neuro-Kard, Poznan, Poland
🇺🇸University of California, Irvine, Irvine, California, United States
🇦🇹Wilhelminenspital der Stadt Wien, Wien, Austria
© Copyright 2025. All Rights Reserved by MedPath